Skip to main content

Advertisement

SpringerLink
Log in

A case of polycyclic Sweet’s syndrome arising from azacitidine injection sites in myelodysplasia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Alencar C, Abramowtiz M, Parekh S, Braunshweig I, Jacobson M, Silverman L, Verma A (2009) Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. Am J Hematol 84(10):688–689

    Article  CAS  Google Scholar 

  2. Tiwari SM, Caccetta T, Kumarasinghe SP, Harvey N (2018) Azacitidine-induced Sweet syndrome: Two unusual clinical presentations. Australas J Dermatol 59(3):e224–e225

    Article  Google Scholar 

  3. Bonazza S, Dalton B, Hardin J, Metelitsa A (2015) Histiocytoid Variant of Sweet syndrome associated with azacitidine and recurrence upon rechallenge. Can J Hosp Pharm 68(4):339–341

    PubMed  PubMed Central  Google Scholar 

  4. Tintle S, Patel V, Ruskin A, Halasz C (2011) Azacitidine: a new medication associated with Sweet syndrome. J Am Acad Dermatol 64(5):e77–e79

    Article  Google Scholar 

  5. Trickett HB, Cumpston A, Craig M (2012) Azacitidine-associated Sweet's syndrome. Am J Health Syst Pharm 69(10):869–871

    Article  CAS  Google Scholar 

  6. Roy C, Adam JP, Morin F, Lemieux-Blanchard É, Doucet S, Friedmann D, Belisle A, Charpentier D (2018) Azacitidine-induced pyoderma gangrenosum at injection sites in a patient with myelodysplastic syndrome. Curr Oncol 25(1):e103–e105

    Article  CAS  Google Scholar 

  7. Tseng E, Alhusayen R, Sade S, Buckstein R, Prica A (2015) Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome. Br J Haematol 169(4):461

    Article  CAS  Google Scholar 

  8. Pardo Pastor J, Capafons Redondo S, March Lopez P et al (2017) Image Gallery: Pyoderma gangrenosum in a patient with myelodysplastic syndrome treated with azacitidine. Br J Dermatol 177(3):e68

    Article  CAS  Google Scholar 

  9. Martinelli S, Rigolin GM, Leo G et al (2014) Complete remission of Sweet's syndrome after azacitidine treatment for concomitant myelodysplastic syndrome. Int J Hematol 99(5):663–667

    Article  CAS  Google Scholar 

  10. Lin CH, Yeh SP, Lin TY (2015) Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndrome. Ann Hematol 94(11):1925–1926

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Faculty of Medicine, St. Vincent’s Hospital Melbourne, University of Melbourne, Melbourne, Australia

    William A. Berry & Robert Kelly

Authors
  1. William A. Berry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William A. Berry.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Statement of informed consent

Informed consent was obtained from all individual participants included in the study.

Disclaimer

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berry, W.A., Kelly, R. A case of polycyclic Sweet’s syndrome arising from azacitidine injection sites in myelodysplasia. Ann Hematol 99, 201–202 (2020). https://doi.org/10.1007/s00277-019-03873-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03873-x

Search

Navigation